Skip to main content

Hypoparathyroidism News

FDA Approves Yorvipath (palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) – Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has approved Yorvipath (palopegteriparatide;...

FDA Approves Natpara (parathyroid hormone) for Hypocalcemia in Patients with Hypoparathyroidism

January 23, 2015 – The U.S. Food and Drug Administration today approved Natpara (parathyroid horomone) to control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism, a rare...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

Vitamin D